Independent evaluation of ibrutinib efficacy 3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease.
Susan Mary O'Brien
Research Funding - Pharmacyclics
Richard R. Furman
Consultant or Advisory Role - Janssen; Pharmacyclics
Honoraria - Janssen
Steven E. Coutre
Consultant or Advisory Role - Pharmacyclics
Research Funding - Pharmacyclics
Ian Flinn
Research Funding - Janssen; Pharmacyclics
Jan Andreas Burger
Consultant or Advisory Role - Celgene; Gilead Sciences; Novartis; Pharmacyclics
Research Funding - Celgene; Pharmacyclics
Kristie A. Blum
No relevant relationships to disclose
Jeff Porter Sharman
Consultant or Advisory Role - Celgene
Honoraria - Genentech; Gilead Sciences; Pharmacyclics
Research Funding - Celgene; Genentech; Gilead Sciences; Pharmacyclics
Other Remuneration - Gilead Sciences
Jeffrey Alan Jones
Consultant or Advisory Role - Janssen; Pharmacyclics
Research Funding - Pharmacyclics
William G. Wierda
Consultant or Advisory Role - Pharmacyclics
Research Funding - Pharmacyclics
Weiqiang Zhao
No relevant relationships to disclose
Nyla A. Heerema
No relevant relationships to disclose
Amy J. Johnson
No relevant relationships to disclose
Anh Tran
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Cathy Zhou
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Elizabeth Bilotti
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Danelle Frances James
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
John C. Byrd
Research Funding - Pharmacyclics